This paper describes a model of the immunologic response of the human immunodeficiency virus (HIV) in individuals. It then illustrates how a Receding Horizon Control (RHC) methodology can be used to drive the system to a stable equilibrium in which a strong immune response controls the viral load in the absence of drug treatment. We also illustrate how this feedback methodology can overcome unplanned treatment interruptions, inaccurate or incomplete data and imperfect model specification. We consider how ideas from stochastic estimation can be used in conjunction with RHC to create a robust treatment methodology.
understanding of disease dynamics has progressed. Techniques based around solutions of Ricatti equations may be augmented to solve nonlinear control problems; however, these techniques require that the model be of a certain form and can require frequent state knowledge or estimation. For an example of this sort of technique applied to HIV control see [6] . A potential solution involves using Bellman's principle of optimality, however this involves solving a nonlinear partial differential equation which, in general, is computationally challenging.
Receding Horizon Control (RHC) seeks to gain the benefits of a feedback control while utilizing the computational simplicity of a calculus of variations approach. RHC involves solving a finite horizon open-loop optimal control problem on-line at each sampling instant. There are several design considerations in using this methodology including the process model, the cost function to be minimized, the sampling period, the control horizon, and the method by which the state is obtained at each sampling instant. The method by which the state is obtained at each sampling instant is of special concern as it generally involves some combination of model prediction and noisy measurements. For this problem, we will employ stochastic estimation; in particular, the Extended Kalman Filter (EKF). An excellent survey paper related to the theory behind RHC is [21] . Another source for a description of the multitude of industrial applications of this technique is [23] . This technique has been used several times in the context of HIV control [24, 26] .
The contribution of the present work is that it considers a complex predictive model of HIV dynamics, which has been validated with clinical data (see [1] ), that includes multi-drug therapy, multiple target cells and a compartment accounting for the virus specific immune response. We use RHC in conjunction with stochastic estimation to control HIV infection under poor drug adherence, noisy measurements, and inaccurate model parameters.
The organization of this paper is as follows. In Section 2 we discuss the model of HIV infection studied here. We then describe the specific RHC methodology that we have considered in Section 3. Numerical results for the RHC implementation are presented in Section 4. Situations in which treatments are missed and a state estimator is employed are treated in Sections 5 and 6. The numerical solutions to these two combined problems are illustrated in Section 7. In Section 8 we demonstrate how RHC methodology can be used in situations in which model parameters are allowed to vary in some random manner.
HIV model
A great deal of effort has gone into modeling the physiologic and immunologic response of HIV in individuals. For excellent reviews of the various types of modeling attempts see, e.g. [8, 9, 22] . In our attempt to model the physiologic and immunologic response of the HIV in individuals, we will consider a variation of the model proposed in [8] . It accounts for a variation of drug efficacy based on target cell type. Note that the differentiation between target cells is based on cell type as opposed to cell location or longevity. A second chief component of this model is the modeling of the bodies HIV specific immune response. This aspect of the model is based on a Michaelis-Menten nonlinearity saturation as proposed by [7] . This specific model has been studied in [3, 4, 1, 6] .
This model captures some of the chief characteristics of HIV infection that we would like to consider. In addition to modeling the body's HIV specific immune response and differentiating between types of target cells, this model also accounts for multi-drug therapy, both reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs). RTIs interfere with the viral RNA-to-DNA synthesis thus blocking the introduction of viral DNA into the cells genetic information. Without this step the cells will not produce new virus. PIs attack the virus at the stage at which infected cells assemble new viral cells thus producing non-infectious viral cells. An important physiological aspect of this model is its ability to reproduce a low non-zero viral load in the presence of multi-drug therapy. The model also possesses multiple stable equilibria including a viral dominant equilibrium and an immune response dominant equilibrium.
The dynamics of our HIV model are described by the system of nonlinear differential equationsṪ
(1)
The state variables are T 1 , the uninfected CD4+ T-cells; T 2 , the uninfected target cells of a second kind; T * 1 , the infected T-cells; T * 2 , the infected target cells of a second kind; V I , the infectious virus; V N I , the non-infectious virus; and E, the immune effectors. We do not give specific definitions of target cells of second kind and immune effectors. They could, for example be related to macrophages and cytotoxic T-lymphocytes, respectively. Table 1 
RHC Methodology
As stated before, RHC seeks to gain the benefits of a feedback control while utilizing the computational simplicity of a calculus of variations approach. Thus, there are several basic components to the methodology. First, there are the model equations which we use to predict system behavior and compute the optimal control. There is the estimation of the current state, which can be done with a combination of measured data and predicted output. We will use the methodology described in [12] , however there are a variety of techniques to complete this step. There is also the specific optimal control problem involving a cost function one seeks to minimize. Finally, there is the methodology by which the control horizon, the period over which each optimal control problem is solved, and the period over which this control is used, are selected. Figure  1 is a schematic that illustrates this general process. To formalize this methodology we will present the following mathematical formulation. We will use notation for the RHC methodology that is similar to that presented in [15] . Let [t i , t i+1 ] be a sequence of time intervals. Let t ch,i such that t ch,i ≥ t i+1 − t i be the control horizon. Consider the sequence of problems, O i ,
on the interval [t i , t i+1 ]. In order to be biologically realistic we will also enforce bounds on the control, u min ≤ u(t) ≤ u max . Note that for this problem the control is the efficacy of the drug dose and thus we will write u = ( 1 , 2 ). The solution to each optimal control problem O i can be analyzed and solved in the manner presented in detail in [12] and summarized here. We used a quasi-Newton method BFGS. The code used in this problem can be obtained from the web site http: //www.math.ncsu.edu/~ctk. For more information on this optimization algorithm see [18] .
The RHC methodology can be summarized as follows:
2. Use the control as it is defined on the interval [t i , t i+1 ] to determine the trajectory on the same time interval.
3. Use observations or an estimator to determine x(t i+1 ).
4. Repeat the process over starting at the next time interval t i+1 .
This process is illustrated in Figure 2 . This means that O 0 was solved by minimizing the integral from t 0 to T . However the control was only used from t 0 to t 1 . At this point a new control was computed by solving O 1 on the interval t 1 to t 1 + T . This control was then used from t 1 to t 2 . Note that neither the time intervals nor the control horizon need to be constant.
Our numerical routine to solve each control problem O i , is an iterative method thus requiring an initial iterate. The initial iterate for O 0 was u 0 = 0.5( 1,max , 2,max ). The initial iterate for each subsequent O i was the optimal solution to O i−1 . Two heuristic approaches were used to facilitate numerical computations. One approach was how to choose the initial iterate when the immune response E was stimulated above 200 cells/mm 3 . In this case, the initial iterate was decreased by a factor of 10 as this facilitated convergence to a low dose control that stimulated further immune response. The other was in the case that the ode solver did not converge for a candidate control vector. In this case u p was replaced with 0.99u p and the algorithm proceeded. The optimal control estimation is discussed further in [12] and the full optimality conditions are given in [11] .
Numerical Results: Perfect State Knowledge
For our study we employed the following cost functional
where Q e , R 1 , R 2 , S and θ are weighting coefficients. The maximum values for the drug efficacies for the following simulations are 1,max = 0.7 and 2,max = 0.3. The results of [11] suggest that each optimal control problem O i has a unique solution with the addition of one condition, that φ in (2), the weighting on the final state, is continuous. As φ in (4) is a quadratic function of E this condition holds. Table 2 contains the values for the optimal control problem. The small values of weighting coefficients are used so that the gradient values are of approximately the same magnitude as the control bounds thus improving the efficiency of the optimization.
In this section we will assume that we have perfect knowledge of the state at each point in which a new control is computed. This is not physically realistic, but we will use the EKF to address the problem of lack of state knowledge in Section 6. The initial condition for this problem is a healthy individual with a small amount of free virus introduced to their system. This can be termed acute infection. The specific values for this initial condition are
Our goal is to transfer this infected individual to a healthy immune response dominated equilibrium. The specific values for this state are
This equilibrium has been studied in [2, 3] . We will merely note here that this is a stable equilibrium in the presence of no treatment. We have investigated three cases for how often the control is allowed to change. The treatments are allowed to vary daily, every five days, and every ten days. Note that as the model and control are continuous representations (as opposed to a discrete model) the control values used in between specified treatment values are a linear interpolation. Figures 3-6 depict control and model response for each of these cases. The noninfectious virus V N I has been omitted in the figures as that compartment has no direct effect on any of the other compartments. Figure 3 depicts each one of the state variables as a function of time in days on the left and the corresponding treatment protocol on the right. Note that the healthy cells decline during the treatment interruptions and the free virus and infected cells rebound. The state variable E is the best indicator of the progression toward immune system dominance and can be seen in the lower right box of all the state variables. In Figure 4 we plot in the phase plane of the log of the immune effector versus the log of the virus. Note that in this sort of plot time is an implicit variable with only the two state variables being shown. This plot begins at acute infection and thus relatively low levels of E and V . We can see that the viral load undergoes one increase during infection and four increases during treatment interruptions. It is interesting to see that E decreases during most of the treatment interruption only to increase toward the end of the interruption. Observe that each one of these treatment protocols has treatment interruptions under which the viral load and infected cells rebound, while the number of healthy cells drops. Also note that the frequency with which the control is allowed to vary has a large effect on how long it takes the immune response to be stimulated and for the individual to be transferred to the healthy steady state. When the control is allowed to vary daily the control is largely turned off after 400 days, whereas it is not turned off until approximately 600 days when the control varies every 5 days and 900 days are required when the control is allowed to vary every 10 days. The phase plots in Figure 4 also illustrate the difference in system response when the control is only allowed to vary every 10 days. Note how more interruptions are required and there is a good deal more time where the immune response is declining.
We would also like to determine whether this methodology can be used to transfer a patient from the unhealthy equilibrium to the healthy equilibrium. By unhealthy equilibrium we mean the state This equilibrium represents a physical state in which the immune response has largely been destroyed and a large quantity of infected cells and free virus is present in an individual. Note that this equilibrium is shown to be stable in [2, 3] . Figures 7, 9 and 10 illustrate the model simulations and controls when the initial conditions are given by the unhealthy steady state. Figure 8 depicts the phase plot of the log of the immune effector as a function of the log of the virus. In each one of these situations, even when the control was only allowed to vary every 10 days, the RHC methodology was able to transfer the system to the immune effector dominated equilibrium.
Unscheduled Treatment Interruption

A natural question to pose is what happens if (or when) a patient goes off medication?
This can occur because of new infections, drug side effects, lack of adherence, or a number of other reasons. Open loop methodology has no way to take this into account and will most likely prove insufficient. Feedback controllers can take this treatment lapse into account and adjust the controller. We will examine how RHC performs when a patient disregards the proposed treatment schedule and goes off treatment. of RHC based treatment. Other than this cessation of treatment the experimental design is identical to that presented in Section 4. Figure 11 contains the results from this simulation. Note that this situation requires 6 periods of treatment interruptions whereas the identical situation in which the treatment regiment was followed required only 4 treatment interruptions.
As the immune response is key to the healthy steady state we should examine the effect this treatment interruption has on the immune response. Figure 12 has a comparison of the immune response when the control is allowed to vary daily but in one case the patient adhered to the treatment protocol whereas in the other case the patient went off treatment. First it delays the stimulation of the immune response by approximately 120 days. However it should also be noted that the RHC based treatment strategy was able to overcome the failure to take medication and still transferred the patient to healthy steady state. Figure 13 repeats this situation when the control is allowed to vary every 5 days. Note that when the control can only vary every 5 days the stimulation of the immune response is delayed by approximately 180 days, a longer delay than when the control can vary daily.
Numerical Results: State Estimation
In this section we will address the problem of implementing RHC methodology while relying on the EKF to estimate the state each time a new control is implemented. (In some cases -see ( [5] ) -a more efficient filter might be found, but we use EKF here for simplicity.) RHC is a full-state feedback control technique, thus it requires state knowledge. It does not require state knowledge continually as a Ricatti equation technique does, but it does require an estimate of the state each time a new control is computed. As we have a nonlinear model we choose to employ the EKF. In particular we will consider a formulation based on a continuous process model and discrete time measurements. The general problem we want to consider is given a mathematical model for a physical system, x, corrupted by some process noise, w, and a model for data measurements, z, also corrupted by some noise, v, what is the best, in some sense, estimate for the true physical system.
Mathematically the partial feedback control problem can be stated aṡ
where x(t 0 ) is normally distributed with meanx 0 and covariance P 0 , w(t) and v k are white noise processes uncorrelated with x(t 0 ) and with each other and with means 0 and covariances Q and R, respectively. The formulation of this problem in this manner is presented in [20] . In the case where f and h are linear, the problem reduces to the famed Kalman filter (KF) [17] . Note in this type of state estimation we are trying to estimate statistics which describe a probability distribution on the true state of the process. In the KF the optimal estimate is defined by a normal distribution and thus only the mean,x, and the covariance, P , are needed to completely define the conditional distribution of the state dependent on the data, p[x(t)|(z k )]. See [25] for an excellent introduction to the topic. Immune response E when control is allowed to vary every 5 days. Comparison between following treatment and when treatment was interrupted after 300 days for 10 days. Plot on the top contains the full time interval, while the plot on the bottom focuses on the time period directly after the patient went off medication.
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The EKF attempts to make an estimate of the true state with a "predictor-corrector" type of implementation. First in the "predictor" stage of the algorithm where no data is available and the dynamics are defined by the model, the time update is employeḋ x = f (x, t) (9)
These equations are integrated between time points t k and t k+1 . Then when new data is available the "corrector" stage or measurement update is employed
Note that this method only gives us the mean and covariance. Since f and h are nonlinear the conditional distribution is generally non-normal and would require perhaps infinitely many statistics to fully describe it. Further discussion of the issues related to implementing this filter on this particular model can be found in [12] and [11] .
We will use simulated data created by the model, corrupted by observation noise. The only process noise we will assume is based on the accuracy of the integrator and this is assumed small. Thus we will choose Q = 10 −6 I. The form of the data we are going to use is
where r k is normally distributed with mean 0 and covariance R. For the following experiments R will be of the form
where r 1 = 1000, r 2 = 1000, and r 3 = 10. The control was allowed to vary every 10 days. Data was collected every 10 days. The initial state for the problem was taken as the unhealthy steady state. The initial condition for the estimator was chosen as
where γ is normally distributed with mean 1 and standard deviation 1. Figures 14 and 15 depict the results from this computational experiment. Note that the EKF is rather effective in filtering the noisy data. This allows for the estimate of the initial condition x i to the control problem, O i , to be accurate. This ultimately allows the RHC methodology to be successful in transferring the system to the immune response dominant equilibrium. 
State Estimation and Unscheduled Treatment Interruptions
An additional test of this methodology that we would like to investigate is the case of using the EKF as a state estimator while interrupting the treatment (not in accordance with the proposed treatment schedule) for 10 days after 300 days . Data is collected every 5 days while the control is allowed to vary every 5 days. The parameters for the observation noise for the following experiment are r 1 = 1000, r 2 = 1000, and r 3 = 10. The initial condition for the estimator is chosen as x EKF 0 = 0.3γx true 0 where γ is normally distributed with mean 1 and standard deviation 1. The plots for these simulations can be seen in Figures 16 and 17 . These results are encouraging. We were able to transfer from an unhealthy steady state to a healthy one in the presence of unscheduled treatment interruption and noisy data collected every five days within approximately 800 days. immune system, and incomplete and noisy data. This work also illustrated the relationship between how often the efficacy of the drugs can be changed and the length of time necessary to reach the immune dominant steady state. We also explored the number of interruptions necessary under several detrimental conditions to control HIV infection.
This work sets the stage for a variety of ways mathematical analysis can be used to improve treatment of HIV patients. We have dealt with several of the issues related to designing control based treatment protocols. However this work also begs the question of several courses of analysis related to better designing these protocols. These improvements include the implementation of a filter that incorporates the censored data produced by many viral assays, a pharmacokinetic model of specific drugs, incorporation of the potential for drug-resistance in model and intervals of data collection and treatment changes that are more in line with a clinical condition.
